Kornimate/medical-research-clean huggingface dataset:
a study of ultra high dose diuretics to treat heart failure

Conditions: Heart Failure; With Decompensation

Summary: the purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.


Eligibility criteria:
inclusion criteria: * diagnosis of decompensated heart failure receiving intravenous diuretics * ability to provide informed consent exclusion criteria: * patients on home inotrope medications * patients with chronic kidney disease stage v and end stage renal failure on dialysis * patients lacking the capacity to consent for themselves * known pregnancy or breastfeeding mothers * complex congenital heart disease * allergy to furosemide or bumetanide * respiratory failure requiring non-invasive ventilation (cpap/bipap) or invasive mechanical ventilatory support at the time of randomization * hypotension with systolic blood pressure \<80 mm hg at the time of randomization * acute coronary syndrome * sustained ventricular tachycardia requiring treatment in the last 48 hours * patients weighing ≤ 40 kg
preventing loss of independence through exercise (plié) - pilot

Conditions: Dementia

Summary: the primary goal of this study is to perform a 36-week pilot study with a cross-over design to study the safety and efficacy of a novel integrative exercise program called plié (preventing loss of independence through exercise). plié integrates elements of eastern and western exercise traditions and is specifically designed to target the muscles and movements needed to help individuals with mild-to-moderate dementia maintain physical function and independence.


Eligibility criteria:
inclusion criteria - primary participant: * current participant in the irene swindells center for adult day services in san francisco, ca * recommended by swindells staff * mild-to-moderate dementia * caregiver consent inclusion criteria - caregiver: * provide care to primary participant in the irene swindells center for adult day services in san francisco, ca * can provide information about the primary participant's physical functioning, behaviors, falls, quality of life and own level of stress. exclusion criteria - primary participant: * major current psychiatric illness (e.g., schizophrenia, bipolar disorder) * life expectancy \< 1 year (e.g., metastatic cancer) * inability to assent to study procedures exclusion criteria - caregiver: * any major neurologic disease (e.g., dementia, stroke, parkinson's disease, als) * major current psychiatric illness (e.g., schizophrenia, bipolar disorder) * life expectancy \< 1 year (e.g., metastatic cancer) * evidence of cognitive impairment * inability to consent to study procedures.

Keywords: exercise exercise movement techniques activities of daily living
evaluation of serum galectin-9 level in systemic lupus erythematosus patients and it's association with disease activity and organ damage

Conditions: Systemic Lupus Erythematosus

Summary: study aims to evaluate serum galectin-9 in systemic lupus erythematosus patients and determine it's correlation with overall disease process

systemic lupus erythematosus (sle) is an autoimmune disease characterized by producing large quantities of antibodies directed against self-antigens, particularly double stranded dna (dsdna) and small nuclear rna-binding proteins such as ro, la, sm, and nrnp. sle-associated autoantibodies and high serum interferon alpha (ifn-α) are two important heritable phenotypes in sle which are thought to play a role in disease pathogenesis . the most remarkable feature of the anti dna response is its association with immunopathologic events especially glomerulonephritis . immune complexes containing dna can promote the expression of interferon alpha (ifn-alpha) by a specialized population of dendritic cells known as plasmacytoid dendritic cells . activation of the type i interferon (ifn) system is associated with disease pathogenesis in sle, with affected patients typically demonstrating high concentrations of type i ifn proteins . overexpression of type i ifn-induced genes that includes hundreds of gene transcripts; which is termed interferon signature (ifngs), has been observed in 60-80% of adults and the majority of children with sle . galectin-9 (gal-9) is recognized as a novel, easy to measure biomarker for type1 ifn signatures and galectin-9 could aid in clinical decision making in sle as a marker for disease activity and organ damage. galectin-9 is expressed by t cells, macro-phages, fibroblasts, and endothelial cells, its secreted form is barely detected under physiological conditions, it plays an recognizable role in the regulation of inflammation and immune responses by down-regulating pro-inflammatory t cells.

Eligibility criteria:
inclusion criteria: * clinically diagnosed systemic lupus erythematosus patients. exclusion criteria: * individuals with other autoimmune diseases: 1)rheumatoid arthritis patients 2)dermatomyositis 3)scleroderma 4)mixed connective tissue disease
tvmr with the innovalve system trial - first in human israel

Conditions: Mitral Valve Regurgitation (Degenerative or Functional)

Summary: study to evaluate the safety and performance of the innovalve mitral valve replacement system

the study is a multi-center, first-in-human, prospective, single arm early feasibility study to evaluate the safety and performance of the innovalve mitral valve replacement system

Eligibility criteria:
inclusion criteria: * clinically significant, symptomatic mitral regurgitation * high risk for open-heart surgery * meets anatomical criteria exclusion criteria: * unsuitable anatomy * patient is inoperable * ef\<25%
imaging of cognition, learning, and memory in aging

Conditions: Alzheimer's Disease

Summary: this investigation is designed to study how the brain functions when it is performing explicit memory tasks, and furthermore how the brain systems supporting performance on these tests change as a function of aging. implicit memory tasks may be distinguished from explicit memory tests in that explicit memory characterizes the directed or intentional recollection of previously learned information or events. in contrast, implicit (or nonconscious) memory is expressed in the facilitation of performance on some task or judgment on a stimulus owing to a prior presentation of that stimulus, without any necessary conscious awareness of the prior presentation. the investigators propose to use functional magnetic resonance imaging (fmri) to measure brain activity during the performance of carefully designed explicit memory tasks. comparison of brain activity during the different test conditions will provide information about the brain areas that are involved in mediating specific aspects of performance. both older and younger individuals will be tested in order to understand age related changes in the brain activity. in order to examine the interactions between participants' differential levels of amyloid burden and their performance on cognitive tasks and fmri neural activation, the investigators also propose pet imaging of older participants.

the basic approach to measuring the brain activity associated with a given cognitive process (or processes) is as follows: it is known that increases in brain neuronal activity are associated with local increases in energy metabolism. under normal circumstances, increases in brain metabolism lead to local changes in blood oxygenation in venules and larger veins. this change in blood oxygenation can be detected imaging methods which are sensitive to the differences in magnetic state between oxygenated and deoxygenated hemoglobin. the ultimate benefit of this research is to better understand how changes in both performance and the brain organization underlying that performance are affected by aging.

Eligibility criteria:
inclusion criteria: * aged 20-30 or 60-70 * residing near columbia university medical center * must be willing and able to participate exclusion criteria: * have a contraindication to pet (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour) * pregnancy * lactating women * current, past, or anticipated exposure to radiation * significant active physical illness
pacemaker holter assessment of the effect of bms-914392 on atrial fibrillation burden

Conditions: Atrial Fibrillation

Summary: the purpose of the study is to determine whether treatment with bms-914392 is safe, well tolerated and associated with a reduction of atrial fibrillation burden in patients with paroxysmal atrial fibrillation and permanent pacemaker.


Eligibility criteria:
inclusion criteria: * paroxysmal atrial fibrillation (af) * programmable dual chamber pacemaker with appropriate arrhythmia diagnostics. * 1-50% af burden on pacemaker interrogation at screening. * women of childbearing potential (wocbp) and men must be using an acceptable method of contraception to avoid pregnancy. exclusion criteria: * persistent or permanent af. * af burden \ 50%. * current or history of neurological diseases and mental disorders. * ejection fraction \< 45%. * severe mitral or aortic valve dysfunction. * tia (transient ischemic attack) within last 12 months. * acute coronary syndrome in the last 2 months. * previous af ablation. * cardioversion in last 3 months. * current kidney or liver disease, or current cancer. * history of neurological and mental disorders. * major surgery within 4 weeks of first dose (cardiac surgery within 4 months). * screening lab test results outside of allowed limits per protocol. * qtcf \> 450 msec.
resistance exercise, metabolism and time of day

Conditions: Metabolic Disease

Summary: the aim of the current study is to determine the effect of time of day on the muscle and metabolic responses to resistance exercises in obese or overweight adults. to achieve this aim we have the following objectives: 1. compare the effects of resistance exercise training performed in the morning vs the evening on insulin sensitivity 2. compare the effects of resistance exercise training performed in the morning vs the evening on gains in muscle mass and strength 3. compare the acute glucose responses to resistance exercise performed in the morning vs the evening


Eligibility criteria:
inclusion criteria: * pass the physical activity readiness questionnaire * body mass index (bmi) \>27kg/m² and limited to 40 kg/m². exclusion criteria: * prior surgery for weight loss * prior history of heart, lung, cancer, endocrine or liver disease * participating in more than 1 hour structured exercise training per week

Keywords: exercise muscle metabolism circadian
igg/igm antibody test in patients who have tested negative or positive for covid-19 with the standard method of covid19 testing.

Conditions: SARS-CoV 2

Summary: the purpose of this study is to evaluate point of care sars-cov2 virus igg/igm rapid test cassette clungene test and correlate it with the standard method of testing in inpatients who have tested positive or negative for covid19.

this is a laboratory testing study using the sars-cov2 virus igg/igm rapid test cassette clungene test to determine the presence of igm and igg antibodies in subjects who have tested negative or positive for covid-19. the study is observational and subjects will be assigned to one of two arms depending on the results of their ncovid-19 test.

Eligibility criteria:
inclusion criteria: * received confirmed covid-19 positive or negative test from sharp healthcare's standard method of testing. * age \>/=18 years old. * access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail. * able to read/write/speak english or spanish fluently. * subjects must have the ability to understand the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information. * hospitalized at the time of consent or recently discharged with leftover blood stored at hospital laboratory exclusion criteria: * impaired cognitive or decision-making capacity (based on the clinical judgment of the pi or designee)

Keywords: coronavirus covid-19 clungene igg/igm antibodies
clinical evaluation of dcb-wh1 in healing of chronic diabetic foot ulcers

Conditions: Chronic Diabetic Foot Ulcer

Summary: the primary objective of this phase 2 study is to evaluate the efficacy of dcb-wh1 ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. the secondary objective of this study is to collect safety information of dcb-wh1 ointment. this is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of dcb-wh1 ointment applied topically to grade 1 foot ulcers (according to wagner grading system) in 50 subjects with diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. ages 20 or older with diabetes mellitus (type 1 or 2) who has a cutaneous ulcer on the foot and present for at least 2 weeks 2. the target ulcer is classified as a grade 1 ulcer according to a modified wagner system, which includes wounds involving the epidermis, the dermis, the hypodermis or the subcutaneous fat but not the tendon or joint capsule. the thickness of aforesaid layers wounds be approximately between 0.2 mm and 8 mm and is ranging in size between 3 and 15 cm2 post debridement. 3. an ankle brachial index ≥0.80. 4. the study ulcer should show "infection control" as judged by the investigator 5. the subject should be free of any necrotic or infected soft and bony tissue. 6. signed informed consent form. exclusion criteria: 1. ulcers caused by venous or arterial insufficiency, osteomyelitis. 2. poor nutritional status (albumin \ 10%), anemia (hemoglobin\<10 g/dl), a leukocyte counts \< 1,000/cumm. 3. requiring prostaglandin treatment. 4. requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy. 5. presence of necrosis, purulence or sinus tracts that cannot be removed by debridement. 6. presence of connective tissue disease, renal failure (\*egfr≦30 ml/min/1.73m2), abnormal liver function (aspartate aminotransferase(ast), alanine aminotransferase(alt)\>2.5x upper limit of normal range), malignancy. 7. vascularization surgery performed \<8 weeks before entry in the study. 8. a history of cerebrovascular events, coronary intervention (stent or coronary artery bypass graft (cabg)) or myocardial infarction, within 6 months prior to study. 9. female patient who has a positive pregnancy test or who is breastfeeding or unwilling to use appropriate contraceptive methods during study.

Keywords: oneness dcb-wh1 dcb-wh1-cp001 chronic diabetic foot ulcers topical ointment
validation of the apnealink sleep screener for obstructive sleep apnea (osa)

Conditions: Obstructive Sleep Apnea

Summary: the primary endpoints for this study are that the al validation will 1) achieve a sensitivity of greater than 80% for ahi values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating strong correlation between the ahi of diagnostic psg and al.

all subjects with suspected sleep disordered breathing (sdb) scheduled for diagnostic polysomnography (psg) will be invited to participate in the study to be tested to determine if they have sleep disordered breathing (sdb), using the apnealink (al) sleep screener. subjects initially will be tested for sdb in the home environment. following an al home test, subjects will undergo a simultaneous, attended diagnostic polysomnography (psg) sleep study and apnealink test for the purpose of confirming and comparing the results between diagnostic psg and the al device.

Eligibility criteria:
inclusion criteria: * adult subjects ( greater than 18 years of age) of either gender or any race * suspected sleep disordered breathing * untreated sleep disordered breathing * willingness to use al at home within 2 days of receipt and instruction on the al * willingness to use al at home and undergo psg within 2 to 4 weeks of completing the at home al test exclusion criteria: * any subject requiring home oxygen therapy * any subject currently receiving positive airway pressure therapy
biomarkers in bone marrow samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of bone marrow from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this research study is looking at biomarkers in bone marrow samples from young patients with acute myeloid leukemia.

objectives: * to study the effect of niche mesenchymal stromal cells (msc) exposure on micrornas (mir) expression in pediatric aml at different time points and compare those profiles to the mir profiles at baseline. * to focus on four pediatric aml-specific mirs (mir34a, mir538e, mir193e, and mir198) which show the most significant differential expression after in vivo niche exposure at four months (hematogenous spread). * to determine whether altered mir expression reflects or causes the metastatic invasion pattern of aml. outline: bone marrow-derived mesenchymal stromal cell (msc) samples are implanted subcutaneously in nod/scid mice. cells are then harvested at day 0, 1 month, and 4 months post-implantation. mirna is isolated and analyzed by ilumina microrna expression profiling single beadchip. the obtained data is then analyzed by the illumina genome studio analysis software.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * fresh human bone marrow samples obtained from orthopedic surgery at the tissue donation program of the feinstein institute and the children oncology group (cog) myeloid disease biorepository patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies
the correlation between the thickness of lipid layer and the meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction

Summary: the purpose of this study is to assess the correlation between the thickness of lipid layer and the meibomian gland dysfunction.


Eligibility criteria:
inclusion criteria: * patients who underwent the meibomian gland dysfunction through the signs. exclusion criteria: * eye surgery history

Keywords: meibomian gland dysfunction lipid layer thickness
a study of impt-514 in active refractory lupus nephritis (ln) and systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus; Lupus Nephritis

Summary: this is a phase 1/2, multi-center, open-label study evaluating the safety and efficacy of impt-514, a bispecific chimeric antigen receptor (car) targeting cluster of differentiation (cd)19 and cd20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. impt-514 treatment consists of a single infusion of car-transduced autologous t cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. individual participants will remain in the active post-treatment period for approximately 1 year. participants will continue in long-term follow-up for 15 years from treatment.


Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent 2. age 18 years of age or older 3. weight \> 45 kg at enrollment 4. adequate blood pressure control 5. on stable background therapy for autoimmune disease (ln, sle) with stable dose of autoimmune disease medications for at least 4 weeks prior to screening 6. diagnosis of sle by 2019 european league against rheumatism (eular)/american college of rheumatology (acr) classification criteria or 2012 systemic lupus collaborating clinics (slicc) criteria, including positive ana or positive anti-dsdna 7. positive anti-nuclear antibody (ana), anti-dsdna (double stranded dna) or anti-smith antibody at screening 8. sle participants: sledai-2k ≥ 6 points, with at least 4 points on clinical, non-laboratory items 9. sle participants: british isles lupus assessment group (bilag) 2004 level b in 2 or more organ systems, or bilag level a in 1 or more organ system 10. physician global assessment ≥ 1 on 0 to 3 visual analogue scale (vas) 11. ln participants: active, biopsy-proven, proliferative ln class iii or iv by 2018 international society of nephrology/renal pathology society (isn/rps) criteria other protocol-defined criteria apply. exclusion criteria: 1. any clinically significant underlying illness, other than sle and ln, which would pose a safety risk or concern, as determined by the investigator 2. any other systemic autoimmune condition 3. rapidly progressive glomerulonephritis 4. active central nervous system (cns) lupus 5. history of allogeneic bone marrow or stem cell transplantation or solid organ transplantation 6. history of prior b cell directed cell therapy, including car t treatment, autologous or allogeneic, as well as prior bispecific or t cell engager therapy 7. drug-induced sle other protocol-defined criteria apply.

Keywords: car t-cell cd19/20 cd19 cd20 lupus nephritis ln systemic lupus erythematosus sle active refractory systemic lupus erythematosus active refractory lupus nephritis
mk0916 in patients with type 2 diabetes and metabolic syndrome (0916-005)

Conditions: Diabetes Mellitus, Type 2; Metabolic Syndrome

Summary: this study will test the safety and effectiveness of mk0916 in patients with type 2 diabetes mellitus and metabolic syndrome. this is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * have type 2 diabetes * 18 to 65 years of age exclusion criteria: * history of type 1 diabetes mellitus * have been treated with insulin in the past 8 weeks * on a weight loss program and have ongoing weight loss * taking weight loss medication * have had surgery requiring general anesthesia in the past 30 days or have a planned surgery * have taken another investigational drug in the last 8 weeks * have active liver disease * have a history of major surgery involving gastric or intestinal bypass